Androgen ablation induces tenascin expression in the rat prostate.
Tenascin is a glycoprotein of the extracellular matrix of mesenchymal derived tissue compartments. Although the DNA sequences that code for tenascin production are known and the protein structure is well characterized, little is known about regulation of tenascin expression. Therefore, we are interested in hormonal aspects of tenascin expression. In this study, we addressed the question if androgen deprivation and prostatic involution would influence tenascin expression in the prostate. Methodologically, in two series of experiments, intact and orchiectomized testosterone propionate substituted male rats were subjected to one of the following hormonal treatments: a) flutamide, b) the antiandrogen casodex, and c) cyproterone acetate (CPA). As controls in each series, we used untreated controls and orchiectomized rats. After a period of 14 days of treatment, prostates were removed. Tenascin immunostaining of the sectioned specimen from the control and the hormonally treated animals demonstrated the following: 1) Little, if any tenascin immunoreactivity was detectable in prostates of untreated animals. 2) Androgen deprivation with either treatment resulted in tenascin expression in the stroma of the prostates. 3) Tenascin expression appeared to be variable both semiquantitatively and in the staining pattern detectable except in prostates treated with CPA, in which we observed the most uniform and most widespread staining pattern. From these results, we conclude that androgen deprivation induces tenascin expression in the stroma of the involuting prostate. Remodelling of the extracellular matrix of the stroma, known to appear in the process of prostate involution by androgen ablation, represents a process which has not been discussed with tenascin expression so far.
Vollmer
G
G
Institute for Biochemistry and Endocrinology, Medical University, Lübeck, Germany.
Michna
H
H
Ebert
K
K
Knuppen
R
R
D000726:Androgen Antagonists / Q000494:pharmacology*; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D015816:Cell Adhesion Molecules, Neuronal / Q000096:biosynthesis*; D017373:Cyproterone Acetate / Q000494:pharmacology; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis*; D005485:Flutamide / Q000494:pharmacology; D008297:Male; D009570:Nitriles; D009919:Orchiectomy; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D019063:Tenascin; D013739:Testosterone / Q000494:pharmacology; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D009570:Nitriles; D019063:Tenascin; D014105:Tosyl Compounds; D013739:Testosterone; D017373:Cyproterone Acetate; D005485:Flutamide; C053541:bicalutamide